Novel oral chemotherapy agents.

被引：4

作者：

Royce M.E. ^{[1
]}

Hoff P.M. ^{[1
]}

Pazdur R. ^{[1
]}

机构：

[1] Department of Gastrointestinal Oncology and Digestive Diseases, The University of Texas MD Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, 77030, TX

来源：

Current Oncology Reports | 2000年 / 2卷 / 1期

关键词：

Clin Oncol; Irinotecan; Capecitabine; Temozolomide; Thymidine Phosphorylase;

D O I：

10.1007/s11912-000-0008-x

中图分类号：

学科分类号：

摘要：

The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens. Recently, interest in oral administration of chemotherapy has been stimulated by the discovery of oral fluoropyrimidines, which appear to possess at least an equivalent efficacy and the potential to reduce toxicity compared with intravenous therapies. Using rational drug design, several oral fluoropyrimidines have been developed, including capecitabine, UFT (tegafur and uracil), eniluracil plus oral 5-fluorouracil (5-FU), and S-1. In addition to the oral fluoropyrimidines, other novel agents available for potential oral administration include irinotecan and temozolomide.

引用

页码：31 / 37

页数：6

共 196 条

[31]

Budman D(1997)Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule Invest New Drugs 15 123-128

[32]

Meropol NJ(1998)Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule Cancer Invest 16 145-151

[33]

Reigner B(1990)Enhancement of the antitumor effects of 5-fluorouracil by folinic acid Pharmacol Ther 47 1-19

[34]

Cassidy J(1994)Phase II trial of uracil and tegafur (UFT) plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma J Clin Oncol 12 2296-2300

[35]

Dirix L(1995)A fixed-ratio combination or uracil and ftorafur (UFT) with low-dose leucovorin: an active oral regimen for advanced colorectal cancer Cancer 75 782-785

[36]

Bissett D(1995)Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: a phase II study Eur J Cancer 31A 2215-2219

[37]

Villalona-Calero M(1999)Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract] Proc ASCO 18 1009A-1009A

[38]

Weiss G(1999)Randomized comparative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer Proc ASCO 18 1015A-1015A

[39]

Burris H(1992)Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil J Biol Chem 267 5236-5242

[40]

Olencki T(1996)Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase J Clin Oncol 14 3085-3096

← 1 2 3 4 5 6 7 8 9 10 →